000			03612nam a2200421 i 4500
988			_aSpringer_BiomedLife_2019
999			_c115893 _d115893 _x1
001			115893
003			ESmaUEC
005			20230110040242.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190713s2019 gw | s |||| 0|eng d
020			_a9783030201869
024	7		_a10.1007/978-3-030-20186-9 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQP364.7 _b2019 EB
245	0	4	_aThe Nociceptin/Orphanin FQ Peptide Receptor _cedited by Mei-Chuan Ko, Girolamo Caló.
250			_a1st ed. 2019.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2019
300			_a1 recurso en línea (X, 417 páginas) _b 78 ilustraciones, 21 ilustraciones a color
336			_aTexto _btxt _2rdacontent
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aHandbook of Experimental Pharmacology _x0171-2004 _v254
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aPART I. The N/OFQ-NOP Receptor System -- 1. The History of N/OFQ and the NOP Receptor -- 2. NOP-Targeted Peptide Ligands -- 3. NOP-Targeted Nonpeptide Ligands -- 4. Pharmacological Assays for Investigating the NOP Receptor -- 5. Electrophysiological Actions of N/OFQ -- 6. NOP Receptor Signaling Cascades -- 7.Regulation of the Genes Encoding the ppN/OFQ and NOP Receptor -- PART II. Biological Actions of NOP Ligands -- 8.NOP-Related Mechanisms in Pain and Analgesia -- 9. NOP-Related Mechanisms in Substance Use Disorders -- 10. NOP Receptor Ligands and Parkinson's Disease -- 11. NOP Ligands for the Treatment of Anxiety and Mood Disorders -- 12. The Nociceptin/Orphanin FQ System and the Regulation of Memory -- 13. N/OFQ-NOP System in Food Intake -- 14. N/OFQ-NOP System in Peripheral and Central Immunomodulation -- 15. N/OFQ-NOP System and Airways -- 16. Effects of NOP-Related Ligands in Nonhuman Primates -- PART III. First Clinical Studies with NOP Ligands -- 17. Nociceptin/Orphanin FQ and Urinary Bladder -- 18. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors -- 19. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094) -- 20. Correction to: Electrophysiological Actions of N/OFQ.
520	3		_aThe aim of this book is not only to introduce readers with a broad spectrum of biological actions of the NOP receptor, but also to feature a detailed look at the N/OFQ-NOP receptor system, medicinal chemistry, pharmacology, and clinical data of NOP-targeted ligands. This special volume book - for the first time focusing on the NOP receptor - is designed to serve as a useful reference, stimulate more research on the N/OFQ-NOP receptor system, and lead to more development of NOP-related ligands for several therapeutic applications.
650		7	_2embne _9147745 _aNeurotransmisores
700	1		_aKo, Mei-Chuan _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aCaló, Girolamo _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030201852
776	0	8	_iPrinted edition: _z9783030201876
776	0	8	_iPrinted edition: _z9783030201883
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-20186-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b01/2020 _ek _zSI